Ning Li

31PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Aug 11, 2026
Rethinking Phase I units in the era of immuno-oncology: a three-layer framework.

|Jul 06, 2026
Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

|May 28, 2026
Intrathecal Allogeneic B7-H3-targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunological Dynamics in a Phase 1 Trial.

|May 15, 2026
Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.

|Mar 11, 2026
Target trial emulation in oncology: current use and future directions.

Hui-Yao Huang, Le Wang, Sheng Xu

|Feb 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Minjiang Chen, Iurie Bulat, Marina Maglakelidze

Pageof 6

Frequent Collaborators

2 joint publications

Yale Jiang

2 joint publications

Yuan Fang

2 joint publications

Wei Guo

1 joint publications

Yuan Li